Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 10/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6385253 | 0.93 | CACNA1G (0.48) | CACNA1GMAPTLMNATP53RAB9A | |
| SCHEMBL6386737 | 0.88 | KDM4E (0.46) | MAPTLMNATP53DRD2DRD3 | |
| SCHEMBL6388847 | 0.86 | HTR2C (0.49) | CACNA1GDRD3 | |
| SCHEMBL6387771 | 0.85 | HTR2C (0.49) | CACNA1GDRD3HTR3A | |
| SCHEMBL6391790 | 0.84 | HTR2C (0.41) | DRD3 | |
| SCHEMBL6389748 | 0.84 | SMN1; SMN2 (0.47) | GAA | |
| SCHEMBL6391308 | 0.84 | KDM4E (0.43) | DRD2DRD3GAA | |
| SCHEMBL6387774 | 0.82 | MCHR1 (0.43) | MAPTLMNADRD2DRD3GAA | |
| SCHEMBL6386620 | 0.82 | MCHR1 (0.43) | MAPTLMNADRD2DRD3GAA | |
| SCHEMBL6391002 | 0.82 | HTR2C (0.46) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | claimed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | CACNA1G 597/4885MAPT 4133/4885LMNA 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.